特一药业(002728) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥687,785,167, representing a decrease of 35.55% compared to ¥1,067,212,110 in 2023[19] - The net profit attributable to shareholders for 2024 was ¥20,495,003.39, a significant decline of 91.90% from ¥253,175,789.62 in the previous year[19] - The net cash flow from operating activities was negative at -¥22,549,753.56, down 111.36% from ¥198,557,705 in 2023[19] - Basic earnings per share for 2024 dropped to ¥0.04, a decrease of 92.73% compared to ¥0.77 in 2023[19] - Total assets at the end of 2024 were ¥2,400,875,824, reflecting a decrease of 4.45% from ¥2,512,636,670 in 2023[20] - The net assets attributable to shareholders decreased by 12.22% to ¥1,764,933,238 at the end of 2024 from ¥2,010,681,910 in 2023[20] - The company reported a weighted average return on equity of 1.10% for 2024, down from 16.57% in 2023, indicating a significant decline in profitability[19] Dividend Distribution - The company plans to distribute a cash dividend of ¥0.5 per 10 shares to all shareholders, with no stock dividends issued[3] - The proposed cash dividend distribution is RMB 0.50 per 10 shares (including tax), with a total cash dividend amounting to RMB 25,029,009.70 (including tax)[169] - The total distributable profit at the end of the reporting period is RMB 353,494,039.54, with the cash dividend amount representing 100% of the total profit distribution[166] - The company has not proposed any stock dividends or capital reserve transfers in the current profit distribution plan[168] Market Position and Strategy - The company has a strong market position in traditional Chinese medicine, with its core product, the cough remedy, ranked among the top ten brands in its category[33] - Recent government policies are expected to provide significant opportunities for the development of traditional Chinese medicine, enhancing the industry's growth potential[34] - The company is focusing on enhancing product quality and marketing strategies to improve its competitive edge in the market[33] - The company is actively exploring innovative development paths to strengthen its competitiveness in the innovative drug sector[30] - The company aims to enhance brand awareness and reputation while reducing shipments of Cough Relief Tablets, resulting in higher sales expenses[43] Research and Development - The company holds 35 invention patents, 23 design patents, and 8 utility model patents as of the end of the reporting period[41] - The company is advancing several R&D projects aimed at improving product competitiveness and market share, including consistency evaluations for various pharmaceutical products[65] - The total R&D investment amounted to 47,347,279.88 in 2024, representing 6.88% of operating revenue, an increase of 1.90% from 2023[67] - The company is focusing on the innovation and development of traditional Chinese medicine, aligning with national policies to promote the industry, and plans to leverage its existing product lines for market expansion[104] Operational Challenges - The company has indicated potential risks in its future operations, which investors should be aware of[3] - The company has not made any changes to its main business since its listing[19] - The company has seen a significant increase in shareholding for Xu Songqing, with a total of 40,572,000 shares after the rights distribution[133] - The lengthy and costly drug development process presents risks, but the company is committed to improving its R&D capabilities and collaborating with external research institutions to advance high-quality generic drug projects[119] Environmental Compliance - The company holds valid pollution discharge permits for its subsidiaries, with expiration dates ranging from 2025 to 2027[190] - The company adheres to multiple environmental protection laws and industry standards, including the "Water Pollutants Discharge Standards for Traditional Chinese Medicine"[189] - The company has established a comprehensive internal control system to prevent financial misstatements and fraud[184] - The company has developed an environmental self-monitoring plan, conducting daily monitoring of pollutant emissions and engaging third-party testing agencies for regular assessments[200] Governance and Management - The company has established a robust governance structure, complying with relevant laws and regulations[126] - The company actively protects the rights of minority shareholders during shareholder meetings[126] - The company has a dedicated investor relations management system to ensure transparent communication with investors[127] - The company has a total of 901,600 shares held by the financial director after a stock option exercise[133] Employee and Talent Management - The company has implemented a training plan to foster talent development aligned with its strategic goals[157] - The company has a total of 1,341 employees, with 705 in the parent company and 636 in major subsidiaries[155] - The professional composition includes 722 production personnel, 203 sales personnel, and 290 technical personnel[155] - The management team includes experienced professionals with backgrounds in pharmaceutical technology and management[145]